MEDSIR and Debiopharm launch Phase Ib/II WIN-B trial investigating the combination of Debio 0123 and Trodelvy in advanced HR+/HER2- and triple-negative breast cancers.
Repare Therapeutics is set to report Phase 2 dose expansion data for lunresertib plus camonsertib in platinum-resistant ovarian and endometrial cancers in December.